Candidiasis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Candidiasis Therapeutics Market was valued at USD 3.32 Billion in 2024, and is expected to reach USD 4.78 Billion by 2030, rising at a CAGR of 6.22%. Candidiasis, a fungal infection primarily caused by Candida species, remains a growing healthcare concern across all age groups. Manifesting in forms such as oral thrush, vaginal infections, esophageal candidiasis, and invasive candidiasis, it poses heightened risks for immunocompromised populations - including individuals with HIV/AIDS, cancer patients, and transplant recipients. The widespread and sometimes inappropriate use of antibiotics has further contributed to its rising prevalence. In response, the global therapeutics market is witnessing rising demand for effective antifungal treatments. With a diverse and expanding patient base, the need for innovative and targeted therapies continues to drive investment and advancements within the market.

Key Market Drivers

The Rising Incidence of Candidiasis

Candidiasis, primarily caused by Candida albicans and increasingly by drug-resistant species such as Candida auris, is on the rise globally. In 2024, the CDC reported more than 34,000 cases of candidemia in the United States alone, underscoring a significant year-over-year increase. The emergence of Candida auris, detected in over 40 countries, highlights the infection's expanding global impact.

Key contributing factors include the widespread use of antibiotics, which disrupt healthy microbial balance, and a growing population of immunocompromised individuals - such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. Aging demographics further heighten vulnerability to these infections. As the disease burden escalates, pharmaceutical and biotechnology companies are intensifying R&D efforts to develop advanced antifungal drugs. This momentum is reinforced by the need for therapeutics that are both more effective and capable of overcoming resistance, with many new treatments currently progressing through clinical trials.

Key Market Challenges

Antifungal Resistance

Antifungal resistance poses a major obstacle to candidiasis treatment worldwide. The increasing prevalence of multidrug-resistant strains, particularly Candida auris, has complicated the clinical landscape. In 2023 alone, over 2,400 cases of Candida auris were reported in the United States - nearly doubling from 2020 figures. Resistance to key antifungal classes such as azoles and echinocandins limits treatment options and increases reliance on less effective or more toxic alternatives. This trend is especially concerning in high-risk populations, including immunocompromised patients, where timely and successful intervention is crucial. The challenge underscores the need for continuous innovation and investment in resistance-mitigating therapies.

Key Market Trends

Antifungal Drug Development and Innovation

A leading trend in the Candidiasis Therapeutics Market is the sustained focus on novel antifungal drug development. The rise in drug-resistant infections has prompted pharmaceutical firms to prioritize research targeting resistant Candida species. Innovations include the development of next-generation antifungal agents as well as the exploration of combination therapies, which utilize multiple antifungal drugs to improve efficacy and reduce resistance risk. These advancements reflect a broader movement toward personalized, more effective treatment options, ensuring better outcomes for patients with complex or persistent infections.

Key Market Players

• Basilea Pharmaceutica Ltd
• Astellas Pharma Inc.
• SCYNEXIS, Inc.
• NovaDigm Therapeutics
• Mycovia Pharmaceuticals, Inc.
• Cidara Therapeutics Inc.
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Novabiotics Limited

Report Scope:

In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Candidiasis Therapeutics Market, By Route of Administration:

• Injection
• Ointment
• Oral

Candidiasis Therapeutics Market, By Drug Type:

• Polyene
• Azole
• Echinocandin
• Other

Candidiasis Therapeutics Market, By Anatomy Type:

• Oral Candidiasis
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis

Candidiasis Therapeutics Market, By End-User:

• Hospitals and Clinics
• Retail Pharmacies
• Other

Candidiasis Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Candidiasis Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.